Drilldown: Medicines

Codeine (2)

Other values:

Search

None (13) · (multiple, generic dominant) (1) · Alfenta (1) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Edronax (1) · Fetzima (1) · Heroin (1) · Krokodil (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Nubain (1) · Nucynta (1) · Nuplazid (1) · O-DSMT (1) · Opana (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Surmontil (1) · Talwin (1) · Tofranil (1) · Ultiva (1) · Valdoxan (1) · Vicodin (1) · Vivactil (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Active metabolite of tramadol; mu-opioid agonist (1) · Extremely potent mu-opioid receptor agonist (1) · Highly potent mu-opioid receptor agonist (1) · Irreversible non-selective MAO inhibitor (3) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; fentanyl analogue (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Opioid receptor partial agonist/antagonist; toxic alkaloid (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (6) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of morphine; mu-opioid receptor agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible inhibitor of MAO-A (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Selective mu-opioid receptor agonist (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Ultra-short-acting mu-opioid agonist (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (46) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (46) · 25 mg (1) · 34 mg PO once daily (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (46) · 10 mg, 34 mg capsules/tablets (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (46) · 200 mg/d (1) · 34 mg/d (1) · 360 mg/day (1)

None (45) · Oral (3) · PO (only formulation marketed in the US). (1)

None (45) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Benefit over weeks of dosing (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (45) · 4–6 hours (1) · Chronic daily dosing (1) · Daily dosing (1) · Long (1)

None (45) · 2.5–3 hours (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (45) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not characterized; oral dosing once daily (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (45) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; avoid (1)

None (45) · Rx-only (1) · Rx-only in US (1) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)